Oculis

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: -

Employees: 36

Market Cap: $553.1M

Website

Introduction: Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The firm's pipeline includes multiple product candidates in development such as, OCS-01, a topical retinal candidate for diabetic macular edema, OCS-02, a topical biologic candidate for dry eye disease, and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company was founded in 2016 and is headquartered in Zug, Switzerland.

Clinical Trials

Pivotal Study of OCS-01 Eye Drops in Subjects with Diabetic Macular Edema (DIAMOND-2)

Phase 3

Recruiting

Conditions: Diabetic Macular Edema

Interventions: Drug: Dexamethasone ophthalmic suspension (OCS-01)
Drug: Vehicle

First Posted Date: 2023-12-15

Last Posted Date: 2024-11-04

Lead Sponsor: Oculis

Target Recruit Count: 350

Registration Number: NCT06172257

Locations: 🇺🇸
Oculis Investigative Site - Stanford Byers Eye Institute, Palo Alto, California, United States

Study Evaluating the Efficacy and Safety of OCS-01 Eye Drops in Subjects Following Cataract Surgery

Phase 3

Terminated

Conditions: Inflammation Eye
Cataract
Pain, Postoperative

Interventions: Other: Vehicle of OCS-01
Drug: Dexamethasone Ophthalmic Suspension

First Posted Date: 2023-11-13

Last Posted Date: 2024-12-10

Lead Sponsor: Oculis

Target Recruit Count: 117

Registration Number: NCT06128369

Locations: 🇺🇸
Oculis Investigative Site, Lynchburg, Virginia, United States

Safety and Efficacy of Licaminlimab Ophthalmic Suspension for the Treatment of Dry Eye Disease

Phase 2

Active, not recruiting

Conditions: Dry Eye Disease

Interventions: Drug: licaminlimab
Other: vehicle of OCS-02

First Posted Date: 2023-06-09

Last Posted Date: 2024-02-05

Lead Sponsor: Oculis

Target Recruit Count: 120

Registration Number: NCT05896670

Locations: 🇺🇸
Oculis Investigative Site, Memphis, Tennessee, United States

Efficacy and Safety of Dexamethasone Nanoparticles Eye Drops in Diabetic Macular Edema

Phase 2

Completed

Conditions: Diabetic Macular Edema

Interventions: Drug: Dexamethasone nanoparticles eye drops

First Posted Date: 2022-04-25

Last Posted Date: 2022-06-28

Lead Sponsor: Oculis

Target Recruit Count: 144

Registration Number: NCT05343156

Locations: 🇩🇰
Glostrup Hospital, Glostrup, Denmark

OCS-01: A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

Phase 3

Recruiting

Conditions: Disorders of the Eye Following Cataract Surgery

Interventions: Drug: Dexamethasone
Drug: Vehicle Placebo

First Posted Date: 2021-12-07

Last Posted Date: 2023-01-11

Lead Sponsor: Oculis

Target Recruit Count: 240

Registration Number: NCT05147233

Locations: 🇺🇸
Oculis Investigative Site, Houston, Texas, United States

Pivotal Study of OCS-01 Eye Drops in Subjects with Diabetic Macular Edema (DIAMOND-1)

Phase 2

Recruiting

Conditions: Diabetic Macular Edema

Interventions: Drug: Vehicle
Drug: Dexamethasone ophthalmic suspension (OCS-01)

First Posted Date: 2021-10-04

Last Posted Date: 2024-11-18

Lead Sponsor: Oculis

Target Recruit Count: 497

Registration Number: NCT05066997

Locations: 🇺🇸
Oculis Investigative Site: University Retina - Lemont, Lemont, Illinois, United States

OCS-05 in Patients with Acute Optic Neuritis

Phase 2

Completed

Conditions: Optic Neuritis
Optic; Neuritis, with Demyelination

Interventions: Drug: OCS-05 +SoC (corticosteroid) IV administration
Other: Placebo + SoC (corticosteroid) IV administration

First Posted Date: 2021-02-21

Last Posted Date: 2025-01-06

Lead Sponsor: Oculis

Target Recruit Count: 36

Registration Number: NCT04762017

Locations: 🇫🇷
Hospices Civils de Lyon, Lyon, France
🇫🇷
CHU - Nice, Nice, France
🇫🇷
CIC Neurosciences - La Pitié Salpêtrière, Paris, France

and more 1 locations

OCS-01 in Treating Inflammation and Pain in Post-cataract Patients

Phase 2

Completed

Conditions: Pain, Postoperative
Inflammation Corneal

Interventions: Drug: OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL
Drug: Placebo

First Posted Date: 2019-10-17

Last Posted Date: 2023-01-17

Lead Sponsor: Oculis

Target Recruit Count: 153

Registration Number: NCT04130802

Locations: 🇺🇸
Medical cennre, Petaluma, California, United States
🇺🇸
Medical center, San Antonio, Texas, United States

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy